NCT05393388Active, not recruiting
Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study
Source: ClinicalTrials.gov · Last updated 26 Nov 2025
Brief summary (registry, in English)
We will conduct a Tau PET scan in cognitively normal older adults, enrolled in the Aging Brain Cohort Dedicated to Diversity Study (ABCD2-Tau) study at the University of Pennsylvania's Penn Memory Center/Alzheimer's Disease Core Center (PMC/ADC).Study duration will generally be a one-day study visit for PET imaging, but all subjects will be followed annually as part of their participation in the ABCD2 study. Findings from this study will likely provide insight into the mechanisms and distinctions of age-related cognitive decline and that of preclinical Alzheimer's Disease.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 111 (actual)
- First submitted
- 16 May 2022
- Start date
- 6 Jul 2022
- Primary completion date
- May 2027
- Lead sponsor
- University of Pennsylvania
- Diseases
- Alzheimer disease
- NCT number
- NCT05393388
What you commit to
- Study type: Observational
- Participants enrolled: 111
- From 6 Jul 2022 to the primary completion date, May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study, including major depression and prior head trauma.
Other illness
- Have evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET scan.
- Have a history of significant ongoing alcohol or substance abuse or dependence based on self-report.
Other
- Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician.
- Women of child bearing potential
- The inclusion / exclusion criteria will be ascertained through self-report in conjunction with any medical history available through the participant's medical or research records (EPIC or the ADC database)\*
Who the study is looking for
- Males and females African Americans ≥ 65 years of age.
- Part of the ABCD2 longitudinal cohort, protocol 844047, of the PMC/ADCC with consensus conference designation of normal cognition.
- ABCD2 longitudinal visit must be completed or scheduled to be completed within 1 year prior to the \[18F\]AV-1451 TAU PET scan.
- A brain MRI must be performed within 1 year prior to their study \[18F\]AV-1451 TAU PET scan date and be deemed of adequate quality that the scan may be used for study analysis, including 3T high-resolution imaging of medial temporal lobe structures.
- An amyloid PET scan completed or scheduled within 1year of their study \[18F\]AV-1451
- Women must be post-menopausal or surgically sterile.
Age in the registry: 65 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital of the University of Pennsylvania - Penn Memory Center Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.